Evaluation of esophageal cancer drugs fluorouracil

By | March 20, 2012

Fluorouracil (5-FU) are widely used to treat breast cancer , gastrointestinal cancer, head and neck cancer and other malignant tumors, the first choice for the treatment of colorectal cancer drug. Now that's more effective than continuous intravenous injection.
FU evaluation, summarized a large number of clinical trials the following conclusions can be drawn: CF plus 5-FU combination therapy can enhance the effectiveness, efficiency more than 25% -35%, but no significant effect on survival; CF and 5 – FU in combination, can reduce the amount of 5-FU (less than 600mg/ml); high-dose and low-dose CF CF plus 5-FU's efficacy is insignificant, but the pharmacokinetic point of view, to use moderate doses The CF is better; in CF plus 5-FU dose toxicity low, few patients with severe life-threatening toxicity.
According to clinical experience, we recommend first with 200mg / the CF within the 15-30min intravenous injection or intravenous infusion, and then 5-FU500mg/ml in him continuous intravenous infusion for 5 days, repeated every 21-28 days. Evaluation of fluorouracil, has been reported with continuous infusion 5-FU combined DDP, CBP (card lead), PYM (PYM) or BLM (bleomycin) treatment 41 cases were newly diagnosed esophageal cancer, period 30 days, to complete 2 cycle assessment.
Evaluation of fluorouracil results: CR0 cases, PR23 cases, MR10 cases, RR56.1%. That 5-FU is the most commonly used chemotherapy drugs, the low dose toxicity of continuous intravenous administration of small, high efficacy.

Leave a Reply

Your email address will not be published. Required fields are marked *